Utility of [F-18] fluoroDOPA for neonatal hyperinsulism: A Phase II

[F-18] 氟多巴治疗新生儿高胰岛素血症的效用：II 期

• 批准号: 7373391
• 负责人: Chaitanya R. Divgi
• 金额: $ 32.01万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-15 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7373391
• 关键词: Utility; 18; fluoroDOPA; neonatal; hyperinsulism

DESCRIPTION (provided by applicant): Congenital hyperinsulinism (CHI) is a rare condition that affects approximately 1 in 500,000 infants in the United States. The total prevalence has been estimated to be less than 200,000. Treatment of this disease necessitates surgical removal of the pancreas to control hyperglycemia. Infants with focal lesions are potentially curable by local resection. There are no currently available methods for identifying these focal lesions prior to surgery. A preliminary study being conducted at the applicant's institution suggests that positron emission tomography (PET) with 18F-labeled L-fluoro-dihydroxyphenylalanine (F-DOPA) is useful for identifying and localizing focal lesions. Imaging with F-DOPA will enable selection of surgical approach in children with hyperinsulinism. The applicant's proposal investigates the utility of F-DOPA PET as a noninvasive tool to guide biopsy and nature of pancreatectomy (total versus lesion resection) with focal forms of congenital hyperinsulinism. It is proposed that this study will contribute to the approval of F-DOPA PET for use in image-guided biopsy and pancreatectomy of children with congenital hyperinsulinism, thereby improving the outcome for children with this orphan disease.

描述（由申请人提供）： 先天性高胰岛素（CHI）是一种罕见的疾病，在美国影响约50万婴儿中的1个。 总患病率估计少于200,000。 治疗这种疾病需要手术去除胰腺来控制高血糖。 患有局灶性病变的婴儿可以通过局部切除可以治愈。 目前尚无可用的方法来识别手术前这些局灶性病变。 在申请人机构进行的一项初步研究表明，具有18F标记的L-氟二羟基苯基丙氨酸（F-DOPA）的正电子发射断层扫描（PET）可用于识别和局部化局部病变。 用F-DOPA进行成像，可以选择超胰岛素过度胰岛素的儿童的外科手术方法。 申请人的提议调查了F-DOPA PET作为指导胰腺切除术的活检和性质的非侵入性工具（完全与病变切除），并具有先天性高胰岛素的局灶性形式。 有人提出，这项研究将有助于批准F-DOPA PET用于先天性超胰岛素主义儿童的图像引导活检和胰腺切除术，从而改善了这种孤儿疾病的儿童的结果。